Back

Optimal anticoagulant strategy for periprocedural management of atrial fibrillation ablation: a systematic review and network meta-analysis

31 August 2024 (16:00 - 16:50)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulant therapy for atrial fibrillation in clinical practice Oral Anticoagulation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Tabito Kino

University of Tsukuba, Tsukuba (Japan)

7 More presentations in this session

Presentation thumbnail
Temporal trends of prescription rates, dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in patients with atrial fibrillation
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Persistence and predictors for non-persistence to edoxaban therapy in patients with atrial fibrillation: 4-year follow-up data from the ETNA-AF-Europe study
Associate Professor I. Diemberger (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Impact of resumption of Oral AntiCoagulation therapy (OAC) after GastroIntestinal Bleeding (GIB) on clinical outcomes in patients with Non-Valvular Atrial Fibrillation (NVAF)
Doctor W. Sun (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of NOAC in very elderly atrial fibrillation patients; data from the Korean national health insurance cohort registry
Doctor S. Choi (Incheon, KR)
Abstract Slides Video
Presentation thumbnail
Impact of body weight and body mass index on clinical outcomes of edoxaban therapy in atrial fibrillation patients included in the ETNA-AF-Global registry
Professor G. Boriani (Modena, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulant therapy for atrial fibrillation in clinical practice

The Event

Event poster

ESC Congress 2024

31 August 2024 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Anticoagulation strategy of choice for atrial fibrillation ablation - a network meta-analysis of complication rates
thumbnail
Congress Presentation
Interrupted or uninterrupted direct oral anticoagulants for atrial aibrillation ablation which is the best strategy insights from a network meta-analysis
thumbnail
Congress Presentation
Safety of discontinuing anticoagulation after atrial fibrillation ablation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources